The global urinary retention therapeutics market is anticipated to attain a valuation of US$ 3.44 billion in 2023 and is projected to reach US$ 7.5 billion by 2033, trailing a CAGR of 8.11% during the forecast period.
Increasing rising prevalence of urinary incontinence (UI) and numerous factors like urinary tract infection, weakening of pelvic floor muscles and urethral sphincters, menopause, pregnancy, childbirth, and post-radical prostatectomy surgery in men leads to the development of urinary incontinence symptoms which is expected to fuel market expansion of Urinary retention therapeutics during the forecast period.
In addition, rising cases of urological disorders and development of advanced urinary incontinence devices are expected to boost the growth of urinary retention device market in the projected period. Furthermore, rising demand for minimally invasive operations, as well as aging population that is more prone to urological problems is anticipated to propel growth of the urinary retention device market. Moreover, increasing number of urinary incontinent patients switching from traditional methods to advanced methods is anticipated to rise in the coming years which benefit the market. The expansion of the market is also aided by the increasing risk of related urological disorders among people.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 3.44 billion |
| Anticipated Forecast Value (2033) | US$ 7.5 billion |
| Projected Growth Rate (2023 to 2033) | CAGR 8.11% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market for urinary retention was worth US$ 2.5 billion in 2018, while growing at a CAGR of 6.59 % during the historical period. An article titled “Urinary Incontinence in Postmenopausal Women (2019),” published in the National Center for Biotechnology Information (NCBI), reported that there has been an increase in the incidences of several diseases, like Parkinson's disease, diabetes, multiple sclerosis, etc., which might lead to growing prevalence of urinary incontinence in men and women. This is anticipated to create demand for urinary retention treatment devices during the forecast period. Moreover, the increasing demand for minimally invasive procedures and surging technological advancements are anticipated to fuel market expansion of Urinary retention therapeutics. Surging research and development activities in the field of Urinary Disorders is creating awareness among people and opportunities in the target market, which is anticipated to fuel the market’s growth.
In addition, the surging demand for minimally invasive procedures and mounting technological advancements are anticipated to boost market growth. Surging research and development activities in the field of bladder disorders is creating awareness among people and lucrative prospects in the concerned market. On the other hand, several market players are adopting various strategies, like product launches, developments, acquisitions and mergers, collaborations, to expand their product portfolio in Urinary retention treatment market, which is expected to fuel market growth in the forecast period.
For example, in November 2019, Renovia Inc. declared that the United States Food and Drug Administration’s clearance for its next-generation leva Pelvic Digital Therapeutic, which will be utilized for strengthening pelvic floor muscles and for treating stress, mixed and mild to moderate urgency urinary incontinence in women which will lead to market expansion in the upcoming years. Considering these factors and new developments, the revenue growth of Urinary retention treatment market is projected to be worth US$ 7.5 billion by end of the forecast period, while exhibiting a CAGR of 8.11 %.
Growing cases of prostate cancer driving market growth
Increasing demand for technologically advanced and minimally invasive OTC devices and wearables are propelling research and development activities in urinary retention devices market which is expected to drive market growth during the forecast period. Likewise, MedTech companies are keen on getting Food and drug administration approvals for their next-generation devices for treatment of stress incontinence, especially for treatment of female stress urinary incontinence. This will lead to market’s growth in the coming years.
On the other hand, surging cases of prostate cancer and the awareness of its morbidity is leading to expansion of Urinary retention market. Patients undertaking radical prostectomy surgery are at a high risk of developing post prostatectomy urinary incontinence. Also, radical prostectomy surgery, whether through radiation or surgical dissection, negatively affects the bladders capacity to hold urine or causes spasms that disturbs the urine flow. Additionally, radical prostectomy surgery adversely affects the nerves that regulate bladder function, resulting in bladder disorders. This leads to increasing demand for the devices that help in managing the disease. These factors are expected to propel market growth of Urinary retention treatment during the forecast period.
Principal Consultant
Preference for other therapies restraining market expansion
The growth of the urinary retention treatment device market is restrained by the dearth of awareness about new improvements in urinary disorders treatment devices and post-operative difficulties associated with the devices.
Moreover, increasing cost of treatment and a vulnerable aging population are two variables that negatively affect the need for urinary retention treatment medications. Also, preference for other therapy is further expected to restrain growth of urinary retention treatment market in the forecast period. The industry is also anticipated to be hampered by the surging number of incontinent patients who are unaware of their condition.
North America to dominate the market with maximum share
North America is expected to dominate the market of Urinary retention therapeutics by accounting for 49.6% market share by end of the forecast period. The growth is attributable to early adoption of technologies, vast patient pool of urinary disorder and easy availability and lucrative medical reimbursement policies in the United States and Canada.
On the other hand, strategies adopted by key companies, such as research and development, mergers & acquisitions, and product launches to bolster their market position is another driving factor for the market expansion of Urinary retention therapeutics. For example, In February 2020, Atlantic Therapeutics declared that the United States Food and Drug Administration had granted over-the-counter (OTC) clearance to ‘INNOVO’, a non-invasive, clinically proven, and wearable device for the treatment of stress urinary incontinence in adult females. Therefore, these abovementioned factors are anticipated to fuel the urinary retention treatment devices market in this region during the forecast period.
East Asia driving growth with fastest CAGR
The market in East Asia is projected to exhibit the fastest CAGR of 7.5% during the forecast period. This region offers profitable opportunities for players that operate in the urinary retention treatment devices market owing to its high population base, increasing disposable incomes, and improvements in patient awareness related to advanced urinary retention management.
Japan and China are among the leading countries for prevalence of urinary and bladder disorders in East Asia, which further contributes toward the strong growth reflected by this region in the global urinary retention devices market. Furthermore, lifestyle and demographic changes have led to increase in the cases of gynaecological problems in females at an early age that is expected to benefit the targeted market.
Also, increasing number of hysterectomy cases, surging number of women with early onset of menopause, and growth in obese population are expected to propel market growth in this region as women suffering from above mentioned health conditions are more prone to urinary disorders like urinary retention. These factors are anticipated to fuel the market growth in the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Stress incontinence propelling growth with dominating share
By incontinence type, the stress urinary incontinence segment is expected to dominate the urinary retention therapeutics market with a market share of 38.2% by end of the forecast period. The growth is attributed to rising incidences of stress urinary incontinence witnessed among women.
The epidemiological studies on the stress urinary incontinence in women have reported that around 50% of women with urinary incontinence report symptoms of stress incontinence. Studies have also shown that the rate of stress urinary incontinence among men ranges from 2% to 70% after undergoing prostate surgery. These factors are likely to fuel the segment’s growth during the projected period.
Retail Pharmacies to drive growth with maximum market share
The retail pharmacies are expected to dominate the market by accumulating 57.5% market share by end of the forecast period. This segment is anticipated to grow with a CAGR of 7.1% during the forecast period. The dominating market share of the retail pharmacies is attributed to the long-established nature and widespread availability of these pharmacies around the world. Moreover, most of the consumers still prefer shopping at these channels as it presents product verification, authenticity, and surety. Likewise, these stores offer convenience, customization, and personal assistance to the consumers, which, in turn, is expected to drive the segment growth.
Also, retail stores are the first point of contact for companies to supply products and samples. A surge in the retail business, which provides enhanced access to products, is expected to boost the segment growth during the forecast period. Growing customer sophistication and demand for better value are also anticipated to create growth opportunities in the upcoming years that would lead to growth of this segment.
Start-ups help in determining the future growth opportunities in any market. These new entrants have the potential to generate high returns which directly benefits the expansion of any industry. These start-ups are typically more efficient at transforming inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to sensitive market conditions. Some of the start-ups that will bolster the expansion of Urinary retention therapeutics market are:
The urinary retention therapeutics market is extremely competitive and consists of numerous key industry players. These players are innovating novel delivery systems for treating Urinary retention disorder. This is expected to propel Urinary retention therapeutics market. The key players in this market are: Lupin, Marksans Pharma, Zydus Cadila, Sun Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, Teva Pharmaceutical Industries Ltd, Aurobindo Pharma, Apotex Inc, Ajanta Pharma, Breckenridge Pharmaceutical, Inc., Alembic Pharmaceuticals Limited, and Inventia Healthcare Limited.
Key industry players are inclined on adoption of inorganic growth strategies like acquisition, mergers, partnerships, and collaboration in order to strengthen their product portfolio. This is anticipated to fuel the global Urinary retention therapeutics market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 3.44 billion |
| Market Value in 2033 | US$ 7.5 billion |
| Growth Rate | CAGR of 8.11% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The worldwide market is expected to be valued at US$ 3.44 billion in 2023.
Lupin, Marksans Pharma and Zydus Cadila are key urinary retention therapeutics industry players.
The worldwide market is expected to reach US$ 7.5 billion by 2033.
Growing demand for advanced, non-intrusive OTC devices and wearables is fueling market growth.
The stress urinary incontinence type is likely to remain the key segment in the market through 2033.
1. Executive Summary | Urinary Retention Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Anticholinergic/Antispasmodic Agents
5.3.2. Skeletal Muscle Relaxants
5.3.3. Antidepressants
5.3.4. Alpha Blockers
5.3.5. Topical Estrogens
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Incontinence Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Incontinence Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Incontinence Type, 2023 to 2033
6.3.1. Urge Incontinence
6.3.2. Stress Incontinence
6.3.3. Over-flow Incontinence
6.3.4. Mixed Incontinence
6.4. Y-o-Y Growth Trend Analysis By Incontinence Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Incontinence Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033
7.3.1. Hospital Pharmacy
7.3.2. Retail Pharmacy
7.3.3. Online Pharmacy
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. MIDDLE EAST AND AFRICA
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The USA
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Incontinence Type
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Incontinence Type
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Incontinence Type
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Incontinence Type
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom (UK)
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Incontinence Type
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Incontinence Type
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Drug Class
12.2.3. By Incontinence Type
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Incontinence Type
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Incontinence Type
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Incontinence Type
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Drug Class
14.2.3. By Incontinence Type
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Incontinence Type
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MIDDLE EAST AND AFRICA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MIDDLE EAST AND AFRICA
15.2.2. By Drug Class
15.2.3. By Incontinence Type
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Class
15.3.3. By Incontinence Type
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Drug Class
16.1.2.2. By Incontinence Type
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Drug Class
16.2.2.2. By Incontinence Type
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Drug Class
16.3.2.2. By Incontinence Type
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Drug Class
16.4.2.2. By Incontinence Type
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Drug Class
16.5.2.2. By Incontinence Type
16.5.2.3. By Distribution Channel
16.6. UK
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Drug Class
16.6.2.2. By Incontinence Type
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Drug Class
16.7.2.2. By Incontinence Type
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Drug Class
16.8.2.2. By Incontinence Type
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Drug Class
16.9.2.2. By Incontinence Type
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Drug Class
16.10.2.2. By Incontinence Type
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Drug Class
16.11.2.2. By Incontinence Type
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Drug Class
16.12.2.2. By Incontinence Type
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Drug Class
16.13.2.2. By Incontinence Type
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Drug Class
16.14.2.2. By Incontinence Type
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Drug Class
16.15.2.2. By Incontinence Type
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Drug Class
16.16.2.2. By Incontinence Type
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Drug Class
16.17.2.2. By Incontinence Type
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Drug Class
16.18.2.2. By Incontinence Type
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Drug Class
16.19.2.2. By Incontinence Type
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Drug Class
16.20.2.2. By Incontinence Type
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Drug Class
16.21.2.2. By Incontinence Type
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Drug Class
17.3.3. By Incontinence Type
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Lupin
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Marksans Pharma
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Zydus Cadila
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Sun Pharmaceutical Industries Ltd
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Torrent Pharmaceuticals Ltd
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Teva Pharmaceutical Industries Ltd
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Aurobindo Pharma
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Apotex Inc
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Ajanta Pharma
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Breckenridge Pharmaceutical, Inc
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Alembic Pharmaceuticals Limited
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
18.1.12. Inventia Helthcare Limited
18.1.12.1. Overview
18.1.12.2. Product Portfolio
18.1.12.3. Profitability by Market Segments
18.1.12.4. Sales Footprint
18.1.12.5. Strategy Overview
18.1.12.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Healthcare
November 2022
REP-GB-1451
250 pages
Explore Healthcare Insights
View Reports
Urinary Retention Therapeutics Market
